Endocrine, Metabolic & Immune Disorders - Drug Targets

Author(s): Rashid Mir*, Chandan K. Jha, Naina Khullar, Mohsin Maqbool, Pradeep K. Dabla, Suruchi Mathur, Amal Moustafa, Uzma A. Faridi, Abdullah Hamadi, Mohammad Muzaffar Mir and Faisel M. Abu Duhier

DOI: 10.2174/1871530322666220304220522

DownloadDownload PDF Flyer Cite As
The Role of Inflammatory and Cytokine Biomarkers in the Pathogenesis of Frailty Syndrome

Page: [1357 - 1366] Pages: 10

  • * (Excluding Mailing and Handling)

Abstract

Frailty is a conglomerated elderly disorder that includes multiple abnormalities, like anemia, an increased titer of catabolic hormones, and compromised physiology of most of the body systems. Many studies have established the biomarkers that correlate with physical function and immune aging; however, people can age differently, so chronological age is not a sufficient marker of susceptibility to disabilities, morbidities, and mortality. The pathophysiology of frailty is not clearly understood, but a critical role of enhanced inflammation in the body is hypothesized. Many factors contribute to the development of frailty syndrome, such as pro-inflammatory cytokines, inflammatory markers, inflammatory cytokines, and secosteroids, like vitamin D. This review aims to highlight the role of inflammatory and cytokine biomarkers and vitamin D in the pathogenesis of Frailty Syndrome.

Keywords: Frailty Syndrome, inflammatory biomarkers, cytokine biomarkers, cytokines, adipocytokines, regulatory T-cells (Tregs), T-cell markers, vitamin D.